Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Updated June 2026 · ClinicalTrials.gov

RECRUITINGPhase 2INTERVENTIONAL

Effect of High Dose Intravenous Vitamin C in Severe Pneumonia

Effect of High Dose Intravenous Vitamin C as an Adjunct in the Treatment of Patients With Severe Pneumonia in Intensive Care Unit: a Multi-center, Double-blinded, Two-arm, Placebo-controlled, Randomized Trial

Effect of High Dose Intravenous Vitamin C in Severe Pneumonia (NCT05842382) is a Phase 2 interventional studying Pneumonia, sponsored by Clinical Research Centre, Malaysia. RECRUITING as of the most recent ClinicalTrials.gov update. Talk to your doctor before contacting the trial site.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

This trial is a multicenter, randomized, double-blind, two-arm, parallel-group, placebo-controlled trial to investigate the effect of high dose intravenous (IV) Vitamin C as an adjunct to the standard of care for patients with severe pneumonia versus placebo in ICU.

What Stage of Research Is This?

Phase 2 trials evaluate whether a treatment actually works against Pneumonia and continue monitoring side effects. Phase 2 enrolls larger groups (typically 100–300 patients) and produces the first real efficacy signal. A successful Phase 2 readout is what unlocks the much larger Phase 3 confirmatory trials needed for FDA approval.

This trial is currently recruiting participants. The sponsor has registered the study with ClinicalTrials.gov as actively enrolling, which means new applicants who meet the eligibility criteria can be considered for screening. Trial status can change between updates — confirm current recruiting status with the study contact before traveling for a screening visit.

A target enrollment of 484 participants makes this a sizable late-stage trial. Studies in this range typically have enough power to detect clinically meaningful differences from a comparator and to characterize less-common side effects.

Who May Be Eligible (Plain English)

Who May Qualify: - Patients who are aged 18 and above - Patients who are diagnosed with severe pneumonia - Patients who are mechanically ventilated Who Should NOT Join This Trial: - Known allergy to Vitamin C - Pregnancy - Known history of ongoing concomitant infection - Participation in another clinical trial and/or receipt of investigational drugs within 4 weeks prior to enrollment - Moribund patient with multiorgan failure to the judgement of the treating physician, who is not expected to survive 24 hours - Patient who requires home oxygen therapy or mechanical ventilation, including tracheostomy or non-invasive ventilation, except for CPAP/BIPAP for sleep-disordered breathing - Known history of previous or current diagnosis of renal stones - Known diagnosis of glucose-6-phosphate dehydrogenase (G6PD) deficiency - Known diagnosis of hemochromatosis - Known diagnosis of poorly controlled chronic pulmonary disease, including: - Chronic obstructive pulmonary disease with oxygen therapy - Chronic restrictive pulmonary disease with oxygen therapy - Bronchial asthma on Step 5 of treatment ladder as shown in Pocket Guide for Asthma Management and Prevention - Lung cancer in Stage IV of disease - Known diagnosis of heart failure on anti-failure treatment or requiring mechanical hemodynamic support (e.g. LVAD), with recent hospitalization within 3 months (90 days) from the date of current admission. - Immunocompromised state - Known diagnosis of malignancy and ongoing chemotherapy or radiotherapy as there is evidence that antioxidant supplement before and during treatment was associated with an increased hazard of recurrence - Known diagnosis of malignancy who had completed chemotherapy or radiotherapy with absolute neutrophil count ≤100 cells/mm3 - Known diagnosis of Stage 4 and above chronic kidney disease (GFR \<30 ml/min/1.73m2) and end-stage renal disease on regular dialysis (including peritoneal dialysis or hemodialysis) - Known history of renal transplantation ...See full criteria on ClinicalTrials.gov Always talk to your doctor about whether this trial is right for you.

These are translations of the protocol\'s inclusion and exclusion criteria, simplified for patients and caregivers. The original clinical text appears below. Eligibility is ultimately confirmed by the trial site\'s screening process — this summary is a starting point for a conversation with your doctor, not a final determination.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Patients who are aged 18 and above * Patients who are diagnosed with severe pneumonia * Patients who are mechanically ventilated Exclusion Criteria: * Known allergy to Vitamin C * Pregnancy * Known history of ongoing concomitant infection * Participation in another clinical trial and/or receipt of investigational drugs within 4 weeks prior to enrollment * Moribund patient with multiorgan failure to the judgement of the treating physician, who is not expected to survive 24 hours * Patient who requires home oxygen therapy or mechanical ventilation, including tracheostomy or non-invasive ventilation, except for CPAP/BIPAP for sleep-disordered breathing * Known history of previous or current diagnosis of renal stones * Known diagnosis of glucose-6-phosphate dehydrogenase (G6PD) deficiency * Known diagnosis of hemochromatosis * Known diagnosis of poorly controlled chronic pulmonary disease, including: * Chronic obstructive pulmonary disease with oxygen therapy * Chronic restrictive pulmonary disease with oxygen therapy * Bronchial asthma on Step 5 of treatment ladder as shown in Pocket Guide for Asthma Management and Prevention * Lung cancer in Stage IV of disease * Known diagnosis of heart failure on anti-failure treatment or requiring mechanical hemodynamic support (e.g. LVAD), with recent hospitalization within 3 months (90 days) from the date of current admission. * Immunocompromised state * Known diagnosis of malignancy and ongoing chemotherapy or radiotherapy as there is evidence that antioxidant supplement before and during treatment was associated with an increased hazard of recurrence * Known diagnosis of malignancy who had completed chemotherapy or radiotherapy with absolute neutrophil count ≤100 cells/mm3 * Known diagnosis of Stage 4 and above chronic kidney disease (GFR \<30 ml/min/1.73m2) and end-stage renal disease on regular dialysis (including peritoneal dialysis or hemodialysis) * Known history of renal transplantation * Absence of family members or next of kin for informed consent

Treatments Being Tested

DRUG

Active Ingredient

IV Vitamin C (12g/day)

DRUG

Placebo

IV dextrose 5%

Locations (3)

Trial sites listed on ClinicalTrials.gov for this study. Site activation status can vary — confirm with the specific site before traveling for a screening visit.

Hospital Sultanah Bahiyah
Alor Star, Kedah, Malaysia
Hospital Raja Perempuan Zainab II
Kota Bharu, Kelantan, Malaysia
Hospital Raja Permaisuri Bainun
Ipoh, Perak, Malaysia

How to Talk to Your Doctor About This Trial

Bring the printable summary of this trial — including the NCT ID (NCT05842382), the sponsor (Clinical Research Centre, Malaysia), and the key eligibility criteria — to your next appointment. Your doctor can review the inclusion and exclusion criteria against your medical history, lab values, and current treatments to assess whether you are likely to qualify. They can also help you weigh whether trial participation makes sense alongside your existing care plan.

Useful questions to walk through together: What does the trial protocol require beyond standard care? How long is the active treatment phase, and how long is follow-up? Are there study visits at sites I can reach? Who pays for the trial-specific procedures, and who pays for standard-of-care portions? See our 25 questions to ask about clinical trials guide for a more complete checklist.

Authoritative Sources

The official record for this trial lives on ClinicalTrials.gov — the federal registry maintained by the National Library of Medicine at NIH. For background on how this trial fits into the FDA approval pathway, see the FDA drug approval process. For oncology-specific guidance for patients considering trials, the National Cancer Institute publishes patient-oriented overviews. International trial registries are aggregated by the WHO ICTRP.

Frequently Asked Questions

What is the NCT05842382 clinical trial studying?

This trial is a multicenter, randomized, double-blind, two-arm, parallel-group, placebo-controlled trial to investigate the effect of high dose intravenous (IV) Vitamin C as an adjunct to the standard of care for patients with severe pneumonia versus placebo in ICU. The full protocol is registered on ClinicalTrials.gov and includes the primary outcome measures, eligibility criteria, and study endpoints.

Who can participate in NCT05842382?

Eligibility for this trial depends on the specific inclusion and exclusion criteria set by the sponsor. The plain-English summary above translates the most important criteria into accessible language; the official clinical text is preserved in the collapsible section underneath. Whether you fit any specific trial is a medical decision your doctor needs to confirm — bring the trial information to your treating physician for a full review against your medical history.

How do I contact the trial site for NCT05842382?

Contact information registered with ClinicalTrials.gov is shown in the sidebar of this page. Before reaching out, confirm with your treating physician that this trial is appropriate for your situation. The trial site will then walk you through the screening process to determine final eligibility.

Is participating in a clinical trial safe?

Clinical trials in the United States are regulated by the FDA and overseen by Institutional Review Boards (IRBs) that review the protocol for safety. Risk varies by trial — Phase 1 studies test new treatments in humans for the first time, while Phase 3 trials use treatments that have already passed earlier safety screening. The informed consent document for any specific trial details the known risks and what to expect. Discuss those risks with your physician before deciding whether to participate.

Where can I verify the data on this page?

Every detail on this page comes directly from the ClinicalTrials.gov API. Click "View on ClinicalTrials.gov" in the sidebar to see the official, unmodified record. The federal record is always authoritative; this page is a structured presentation with a plain-English eligibility translation. For background on how clinical trials are regulated, see the FDA drug approval process documentation.

How This Page Is Built

Every field on this page is pulled directly from the ClinicalTrials.gov API v2 — no estimates, no proxies. The plain-English eligibility translation is generated from the original protocol text and reviewed for fidelity to the underlying clinical criteria. The original clinical text remains visible in the collapsible section above so users and clinicians can verify the translation. Read the full methodology for the data pipeline and known limitations.

Related Pneumonia Trials

A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

Phase 3 · Incyte Corporation

A Study of How Ibuzatrelvir is Taken up Into the Blood of Healthy Adults After Taking Different Tablets of Ibuzatrelvir

Phase 1 · Pfizer

COVID-19 Booster and IIV Schedule in Immunocompromised Hosts

Phase 2 · McGill University Health Centre/Research Institute of the McGill University Health Centre

Study Comparing Safety and Immunogenicity of Intranasal COVID-19 Vaccine and mRNA Booster in Healthy Adults

Phase 1 / Phase 2 · ANRS, Emerging Infectious Diseases

A Study to Assess Anktiva in Patients With Long Covid-19.

Phase 2 · ImmunityBio, Inc.

A Clinical Trial to Assess the Safety and PK of OMN6 in HABP or VABP Caused by Acinetobacter Baumannii Complex

Phase 2 · Omnix Medical Ltd

Source: ClinicalTrials.gov API v2 record for NCT05842382. Maintained by the National Library of Medicine at NIH. Public domain. Cite as: "TrialFinderData. NCT05842382. Data: ClinicalTrials.gov."

Medical disclaimer: This page is informational, not medical advice. Talk to your doctor about whether a clinical trial is right for you.

Last updated 2026-06-26 · Data from ClinicalTrials.gov.